Sen. Mark Kelly (D-Ariz.) wants a do-over on President Donald Trump's healthcare cuts. His argument is pretty simple: Americans should be able to get affordable, quality medical care no matter where they happen to live.

Kelly Targets Trump Health Care Cuts

On Wednesday, the Arizona Democrat said in a post on X that he is working to protect access to health care and reduce costs for Americans.

"I'm fighting to make sure health care is there when you need it, no matter who you are or where you live," he said.

Kelly added, "That starts with reversing Trump's healthcare cuts and making sure every American can afford quality care."

Democrats Criticized Trump Health Care Policies

Last month, Gov. Kathy Hochul (D-N.Y.) said ending a Medicare Part D subsidy could have increased prescription drug costs for about 1.3 million New Yorkers, while highlighting state efforts to lower health care expenses.

Previously, Sen. Elizabeth Warren (D-Mass.) said a law signed by Trump had led to significant Medicaid and CHIP coverage losses among children in several states. She also questioned claims about lower prescription drug costs.

Sen. Bernie Sanders (I-Vt.) challenged Trump's claim that drug prices had fallen by 400% to 600%, pointing to the mathematical impossibility of such reductions and promoting legislation he said would cut prescription drug prices in half.

Oz Defends Medicaid and Medicare Changes

Earlier in August, Centers for Medicare and Medicaid Services (CMS) Administrator Dr. Mehmet Oz defended Medicaid changes under the Big, Beautiful Bill Act, citing a $200 billion budget increase, funding for rural hospitals and investments in health care technology and workforce development.

In July, CMS announced it would end the Medicare Part D Premium Stabilization Demonstration after 2026.

Oz said most beneficiaries would see premium increases of less than $10, while the administration continued efforts to lower prescription drug prices.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by MarketDash editors.